May 2024                       

No Study Name/Phase Type Sponsor Population (Gender/Age) Screened Enrolled. (Retention rate) Period
Setshaba Research Centre: Site Initiated Research
1 SRC Geo-Mapping project  click to read more Behavioural SRC ♀ ≥18 yrs Project not a trial:

200 establishments

200 individuals completed surveys

 2021-2022
Other Projects
1 Carraguard/Phase III Microbicide Population Council ♀ 18-40 yrs 3604 2402 (86%) 2004-2007
2 FEM PrEP/Phase III Oral Prep FHI360 ♀ 18-35 yrs 1306 764 (87.5%) 2009-2012
3 ACASI/Phase II Behavioural Population Council ♀ 18-40 yrs 390 200 (100%) 2007
4 SBC preparedness /Phase III Mapping FHI360 Community Mapping N/A >1000 (N/A) 2009-2012
5 HSV 2/Phase III HSV2 Treatment Novartis ♀ ≥18 yrs 16 8 (N/A) 2008-2009
6 Diabetic Peripheral Neuropathic/Phase III Observational Pfizer ♂/♀ ≥18 yrs 8 8 (100%) 2011
7 Tyrosur study/Phase III Wound Healing Engelhard Arzneimittel ♂/♀ ≥12 yrs 55 55 (100%) 2012-2013
8 Impetigo/Phase III Impetigo Treatment Galderma Inc ♂/♀ ≥18 yrs 49 49 (100%) 2012-2013
9 PrEP & Risk Compensation/Phase III Behavioural FHI 360 ♀ 18-35 yrs 547 540 (100%) 2012-2013
10 PrEP & Adherence /Phase III Behavioural FHI 360 ♀ 18-35 yrs 229 229 (100%) 2013
11 TESEC 05/Phase III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 167 164 (98.8%) 2012-2013
12 TESEC 07/Phase II/III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 66 64 (99%) 2012-2013
13 FACTS 001/Phase III Microbicide CONRAD ♀ 18-30 yrs 685 460 (89%) 2011-2015
14 Group B streptococcus/Phase III Observational Novartis ♀ ≥18 yrs 501 501 (N/A) 2013-2015
15 CE/049/ACT/Phase IV Wound Healing  Smith & Nephew ♂/♀ 0-65 yrs 12 12 (100%) 2015
16 HVTN 100/Phase I/II HIV Vaccine HIV Vaccine Trials Network (HVTN) ♂/♀ 18-40 yrs 127 45 (100%) 2015-2017
17 TRIO MPT Acceptability RTI ♀ 18-35 yrs 170 140 (97.9%) 2015-2016
18 RSV (Season 1)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 51 36 (100%) 2015-2017
19 RSV (Season 2)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 171 118 (100%) 2016-2018
20 NC006 (STAND)/Phase III TB Drug therapy TB alliance ♂/♀ ≥18 yrs 45 12 (80%) 2015-2017
21 ASP-CRO-MIC-004/ Bioequivalence Oral Candida Treatment Aspen ♂/♀ ≥18 yrs 10 05 (80%) 2016-2017
22 IMP-Atx/Phase II Impetigo Treatment AntibioTx ♂/♀ 9m – 70 yrs 34 32 (97%) 2018
23 Oral Danarixin/Phase IIa Flu treatment GSK ♂/♀ ≥18 yrs 1 0 2015
24 VISTERA/Phase IIa Flu treatment Pharm-Olam ♂/♀ ≥18 yrs 12 0 2017
25 TB018/Phase III TB Vaccine GSK/IAVI ♂/♀ ≥18 – 50 yrs 1071 467 (N/A) 2014-2019
26 ECHO HIV Risk with Contraception FHI360/University of Washington ♀ 16-35 yrs 1359 864 (N/A) 2015-2019
27 HVTN 108/Phase I/IIa HIV Vaccine HVTN ♂/♀ 18-40 yrs 68 17 (N/A) 2017-2019
28 RSV (Season 3)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 208 165 2017-2019
29 SCHIELD Behavioural RTI ♀≥18, ♂/♀≥18 N/A 6 FGD’s, 10 IDI’s 2018-2019
30 MENACWY CONJ-069/Phase IIb Meningococcal vaccine GSK ♂/♀10-40 yrs 56 49 2018-2019
31 Bacterial Skin Infection/Phase III Therapeutic MSD ♂/♀3mo-<12 yrs 0 0 2019
32 CP40559/Phase III Flu treatment (infants) Roche ♂/♀0-12mo 7 6 2019
33 VICTORIA/Phase III Cardiac Therapeutic MSD ♂/♀≥18 10 6 2018-2020
34 HPV vaccine /Phase III HPV vaccine MSD ♀ 9-26 yrs 20 20 2010-2020
35 Menacwy/Phase III Meningococcal vaccine Pfizer ♂/♀ 12-14 M 87 86 2014-2020
36 HDT TB/Phase IIb TB Treatment Aurum Institute ♂/♀ 18-65 yrs 118 39 2016-2020
37 MV40618/Phase IIIb Flu treatment (Adults) Roche ♂/♀

Index – 12-64 yrs

Household – ≥2 yrs

 5 0 2019
38 SCHIELD PART 2 DCE’s Behavioural RTI ♀18 – 30 24 IDI’s,

400 surveys

 2020-2021
39 HVTN 702/Phase IIb HIV Vaccine HVTN ♂/♀18-35 yrs 647 483 2016 – 2021
40 EPI RSV RSV study GSK ♀ 18-45 301 100 2019 – 2020
41 The CARE Project Behavioural Study DSI NRF Surveys Target 100 N/A 2021
42 NN9924-4309 (Pioneer 12) Diabetes (China) Novo Nordisk ♂+♀ ≥18 8 3 2020 – 2022
43 HVTN 405 Covid observational CoVPN ♂/♀ ≥18 target 15 10 2020 – 2021
44 Crown Coronation Study Covid PrEP WRHI ♂+♀

≥18 and ≤60 & ≥60

 89 77 2020 – 2021
45 ChAdOx1 nCoV-19 Covid Vaccine Bill & Melinda Gates and SAMRC ♂+♀

18-65

 690 418 2020 – 2021
46 2019nCoV-501_Vaccine_Study Covid Vaccine Novavax ♂+♀ 18-64 471 324 2020 – 2021
47 HVTN 705/Phase IIb HIV Vaccine Janssen/HVTN ♀18-35 yrs 225 144 2018-2021
48 NC008/Phase IIc TB Treatment TB Alliance ♂/♀≥18 99 33 2018-2022
49 PrEPARE Study/PrEP Rollout PrEP RTI ♀16-24 yrs 1227 802 2019-2022
50 CoVPN5001 / HVTN5001 Covid observational CoVPN ♂+♀ ≥18 Target 15 6 2020 – 2021
51 ACTIV-2 A5401 COVID IV Infusion PPD ♂+♀ ≥18 Target 75 7 2021 – 2022
52 Alvea-Vax Covid vaccine Alvea LLC & Telis Bioscience Inc. ♂+♀

18 – 65 years

 18 27 Jun 2022 –  Oct 2023
53 STI Zoli Study Phase 3 STI Treatment Oral/Intramuscular GARDP ≥ 12♂/♀ 80 75 Nov/2021 – Dec/2021
54 Sisonke VAC31518COV3012 Phase 3b Covid Vaccine Janssen ♂+♀
18-65		 600 000 Feb/ 2021 – Feb/2023
55 VAC31518COV3001 Covid Vaccine Janssen ♂+♀

≥18 and ≤60 & ≥60

 306 304 2020 – 2022
56 Sisonke 4 (SHERPA) mRNA-1273-P508 Covid Vaccine SAMRC ♂+♀18 and above 500 372 Jun 2022- Sep 2022
57 Insight HIV PrEP study University of Washington ♀

16 – 30 years

 150 150 Sep 2022 – 2023
58 MK8591-022 IMPOWER Oral PrEP MSD ♀   18 – 45 Target 300 161 2021 – 2023
59 C3671008 RSV Vaccine Pfizer ♀   ≥18 and ≤49 target 120 116 2020 – 2023
60 C3671013 RSV Vaccine Pfizer ♂+♀ 60-70 11 4 Dec2021- 2023
61 212171 (RSV MAT-009) RSV Vaccine GSK ♀  18 – 49 Target 250 2021 – 2023

                                             

                                                                                                  

OUR EXPERIENCE

COVID-19
Areas of Expertise
Completed Projects
Current Projects